MZH29
MZH29 is a potent and orally active FLT3 inhibitor. MZH29 shows inhibitory effects on wild-type and mutant FLT3, including the FLT3-ITD, FLT3-D835H/Y/V and FLT3-K663Q mutants. MZH29 retains its potent inhibitory effect against the FLT3-ITD/F691L mutation, a drug resistance mutation against the well-known FLT3 inhibitor, AC220 (HY-13001) . MZH29 can be used for the research of cancer, such as acute myeloid leukemia (AML) [1].
Product Specifications
CAS Number
[2089590-80-5]
UNSPSC
12352005
Target
FLT3
Related Pathways
Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Smiles
O=C(NC1=CC=CC(C)=C1)NC2=CC=C(OC3=CC=NC4=CC(OCCCN5CCOCC5)=C(OC)C=C34)C(F)=C2
Molecular Formula
C31H33FN4O5
Molecular Weight
560.62
References & Citations
[1]Xu B, et al. MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia. Leukemia. 2017 Apr;31 (4) :913-921.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6342746-01 0.2 mL
RNF182, NT (RNF182, E3 ubiquitin-protein ligase RNF182, RING finger protein 182) (Azide free) (HRP)
Ask
View Details 
MBS6342746-02 5x 0.2 mL
RNF182, NT (RNF182, E3 ubiquitin-protein ligase RNF182, RING finger protein 182) (Azide free) (HRP)
Ask
View Details 
